JUST IN: @US_FDA approves combo HIF2 inhibitor Belzutifan PD1 inhibitor Pembrolizumab in adjuvant Kidney Cancer. Approval based on LS022 trial co-led with @tompowles1 presented @ASCO #GU26 adding another approval to @NobelPrize story with @kaelin_lab @DanaFarber @DanaFarber_GU ! Onward ! Great day for patients ! #HIF2 #oncology #labubu dailynews.ascopubs.org/do/li… blog.dana-farber.org/insight…

Excited for the interest in our biomarker work from the urologic oncology community @VincentWenxinXu @PavlosMsaouel @AlexSherryMD @kieko_hara @d_shapiro1 @MDAndersonnews

Hard to believe that these 2 super-stars Drs. @RazaneHChehade @MarcMachaalani are moving on after an amazing 3-yr postdoc fellowships in the @DanaFarber_GU labs Both @PittPediatrics and @YaleIMed are very lucky to have you! Please don’t become @steelers fan or @Yale 🏈 fan!

Vale Richard. I am deeply saddened to lose such a cherished colleague. Richard was a truly extraordinary pathologist - the 'pathologists' pathologist' - who also made generous time for clinicians navigating complex diagnostic cases, understanding that an accurate tissue diagnosis was critical to patient care. His knowledge was vast, his skill exceptional, with an unparalleled eye for accurate tissue diagnoses, and the precision to apply decades of experience where it mattered most. He shared his expertise widely: through consultation on external specimens, through diagnostic and classification frameworks now used worldwide, and as a devoted teacher and mentor. Richard has left an indelible mark on all who had the privilege of working alongside him.  My thoughts are with Richard's family during this difficult time, particularly his wife Katie and children Emily, Matthew, and Lucy. See tribute on @MelanomaAus website >  melanoma.org.au/news/vale-ri…

Somewhere, a patient with pancreatic cancer reads about daraxonrasib and feels hope. Then waits. The science moved fast. The access did not. How do we close that gap, faster? ⏳ @OncoAlert @US_FDA @FDAOncology @OpenMedicineHQ @ASCO #daraxonrasib @RevMedicines

Wrapping up my first #ASCO, from presenting in an oral session to meeting inspiring pioneers in oncology. Grateful for the mentorship and leadership of @DrChoueiri and the @DanaFarber_GU team. @OncoAlert @ASCO

One of my favorite abstracts of this #ASCO26 - reduced denosumab dose intensity (q12w) is NON inferior to q4w in pts with mBC or mCRPC, with improved safety profile in terms of risk of hypocalcemia and osteonecrosis of the jaw Practice changing!! @OncoAlert

Rising star @sara_sarout working with @OncoBellmunt and #FreedmanLab with an outstanding poster on responses to T-Dxd in urothelial carcinoma across all HER-2 IHC scores. @ASCO @OncoAlert @IMG_Oncologists @Uromigos #ASCO26 #mUC

Our superstar fellow @Mustafajsalehmd working with @SashaGusevPosts with an excellent poster presentation on LIF expression as predictive biomarkers in mRCC. Excited to see where this outstanding physician-scientist will match! @VanAllenLab @LabSignoretti @BraunMDPhD @ASCO @OncoAlert @IMG_Oncologists @Uromigos #ASCO26 #KidneyCancer #RCC

RT @DrChoueiri: @DanaFarber_GU ’s very own Prof. Mary-Ellen Taplin opens up the plenary session at #ASCO26 with practice-changing results f…

Congrats to Dr Taplin, all @DanaFarber_GU @DanaFarber and #PROTEUS team on a new frontier in high-risk prostate cancer. Now officially in @NEJM ! nejm.org/doi/full/10.1056/NE…

@chrissweens1 presents level 1B evidence from ENZAMET suggesting Decipher GC >0.85 may identify pts deriving benefit from docetaxel intensification alongside ADT enzalutamide, while no clear benefit signal was observed for GC ≤0.85. #ASCO26 #ProstateCancer @OncoAlert @ASCO @OncBrothers

Congrats to @AtishChoudhury and @CaPsurvivorship for their oral presentations today and how we can adapt treatment interruption and cognitive change from treatment for men with advanced prostate cancer. Huge efforts from them and the study teams @ALLIANCE_org

“Minimizing Toxicity and Maximizing Patient Benefit in Prostate Cancer”, thoughtful discussion by #CatherineMarshall highlighting how precision oncology must also prioritize survivorship, cognition, treatment burden, and thoughtful de-intensification strategies. #ASCO26 #ProstateCancer @OncoAlert @ASCO @OncBrothers

AR PARP intensification strategy in mHNPC by #JoaquinMateo in ZZFIRST: EZ talazoparib achieved a 73% 12-mo PSA <0.2 response rate, with encouraging trends in rPFS and time to castration resistance. Translational analyses also highlighted biologic adaptation to AR inhibition. #ASCO26 #ProstateCancer @OncoAlert @ASCO @OncBrothers

@neerajaiims presents impressive phase III TALAPRO-3 data with concomitant publication in @NEJM: talazoparib enzalutamide significantly prolonged rPFS in HRR-altered mCSPC (HR 0.48), with particularly striking benefit in BRCA-mutated disease and consistent activity beyond BRCA alterations. #ASCO26 #ProstateCancer @OncoAlert @ASCO @OncBrothers

#SebastianMedina presents ST-DoxPCa, an AI/spatial transcriptomics-guided biomarker from CHAARTED that identified mHSPC pts deriving OS benefit from upfront docetaxel (HR 0.53), while low-risk pts showed no clear benefit, highlighting the potential to personalize treatment intensification and avoid unnecessary chemotherapy. #ASCO26 #ProstateCancer @OncoAlert @ASCO @OncBrothers

Excellent discussion by @joshlangMD on the real-world application of emerging biomarkers in prostate cancer: beyond accuracy alone, the key questions remain whether a test is prognostic, predictive, or useful for monitoring, and most importantly, how it changes clinical decision-making. #ASCO26 #ProstateCancer @OncoAlert @ASCO @OncBrothers

#LuciaNappi presents prospective validation data for circulating miR371 in early-stage testicular cancer, supporting its emerging role as a biomarker for active germ cell malignancy and future miR371-informed surveillance strategies. #ASCO26 #TesticularCancer @OncoAlert @ASCO @OncBrothers

Post-pCR management in perioperative MIBC is still unsettled. Standard practice continues planned adjuvant therapy after “sandwich” regimens, even with pCR. Can we safely de-escalate after pCR without losing cure? #ASCO26 @DrChoueiri @TiansterZhang @CathyEngMD @montypal @tompowles1 @brian_rini @cdanicas @GlopesMd @PGrivasMDPhD @nataliagandur @yekeduz_emre @neerajaiims @ASCO @ONCOassist @OpenMedicineHQ @MedwatchKate @scserendipity1 @CParkMD @urotoday @OncLive @crisbergerot @urologysummit @SuyogCancer @Larvol @IMG_Oncologists @ALLIANCE_org